Our results build on previous evidence from bulk tissue at the protein and transcriptomic level that VEGFB, FLT1, FLT4, and NRP1 relate to the clinical progression and neuropathology of AD.16, 18. This evidence concerns the gene VEGFB and Alzheimer disease.